



LKT Laboratories, Inc.

AP-26113

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

## Product Information

Product ID A600002

CAS No. 1197958-12-5

### Chemical Name

Synonym Brigatinib Analog, AP26113

Formula  $C_{26}H_{34}ClN_6O_2P$

Formula Wt. 529.02

Melting Point


Purity  $\geq 98\%$

Solubility

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

**Description** AP-26113 (brigatinib) is a pan inhibitor of ALK. It is a leading candidate for the treatment of ALK+ non-small-cell lung cancer, especially those with major resistance mechanisms. AP-26113 exhibits efficacy against models of ALK+ anaplastic large cell lymphoma in cases where crizotinib, an approved drug for late-stage and metastatic lung cancers, fails due to developed drug resistance.



**Bulk quantities available upon request**

Product ID	Size
A600002	25 mg
A600002	100 mg

**References** Huang W., Liu S., et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. *J Med Chem* 59(10):4948-64 (2016). PMID: 27144831.

Ceccon M., Mologni L., et al. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. *Mol Cancer Res.* 13(4):775;83 (2015). PMID: 25421750.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.